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Abstract 
Background: Culture-adapted Plasmodium falciparum parasites can offer deeper understanding of geographic varia-
tions in drug resistance, pathogenesis and immune evasion. To help ground population-based calculations and infer-
ences from culture-adapted parasites, the complete range of parasites from a study area must be well represented in 
any collection. To this end, standardized adaptation methods and determinants of successful in vitro adaption were 
sought.
Methods: Venous blood was collected from 33 P. falciparum-infected individuals at Goa Medical College and Hospital 
(Bambolim, Goa, India). Culture variables such as whole blood versus washed blood, heat-inactivated plasma versus 
Albumax, and different starting haematocrit levels were tested on fresh blood samples from patients. In vitro adapta-
tion was considered successful when two four-fold or greater increases in parasitaemia were observed within, at most, 
33 days of attempted culture. Subsequently, parasites from the same patients, which were originally cryopreserved 
following blood draw, were retested for adaptability for 45 days using identical host red blood cells (RBCs) and culture 
media.
Results: At a new endemic area research site, ~65 % of tested patient samples, with varied patient history and clinical 
presentation, were successfully culture-adapted immediately after blood collection. Cultures set up at 1 % haemato-
crit and 0.5 % Albumax adapted most rapidly, but no single test condition was uniformly fatal to culture adaptation. 
Success was not limited by low patient parasitaemia nor by patient age. Some parasites emerged even after signifi-
cant delays in sample processing and even after initiation of treatment with anti-malarials. When ‘day 0’ cryopreserved 
samples were retested in parallel many months later using identical host RBCs and media, speed to adaptation 
appeared to be an intrinsic property of the parasites collected from individual patients.
Conclusions: Culture adaptation of P. falciparum in a field setting is formally shown to be robust. Parasites were 
found to have intrinsic variations in adaptability to culture conditions, with some lines requiring longer attempt 
periods for successful adaptation. Quantitative approaches described here can help describe phenotypic diversity of 
field parasite collections with precision. This is expected to improve population-based extrapolations of findings from 
field-derived fresh culture-adapted parasites to broader questions of public health importance.
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Background
Infections from Plasmodium falciparum remain a major 
public health threat around the world. While significant 
progress has been made in controlling malaria disease 
and deaths, recent estimates point to more than 3.2 bil-
lion people at risk for malaria, 200 million infections per 
year, and about 0.6 million deaths per year [1]. Among 
the most affected and most studied are children between 
the ages of two and 12 years in Africa, who account for 
the greatest number of deaths globally [2]. Beyond that, 
understanding variations in disease presentations and 
resistance to malaria counter-measures is of great inter-
est around the world [3, 4], including in South Asia, 
which is understudied and offers interesting contrasts to 
malaria in Africa [5–9].
Culture-adapted malaria parasites can provide power-
ful information on the degree of threat presented from 
resistance to traditional drugs [10–16] and to artemisinin 
and its derivatives [17–24]. Culture-adapted parasites can 
also reveal modes of action of new anti-malarials [25–
27] and physiological mechanisms by which parasites 
develop drug tolerance and ultimately become resistant 
[26, 28–30]. Gene expression in culture-adapted parasites 
has also been used to probe mechanisms of disease [30–
34] and modes of action of protective antibodies [35–38]. 
Many basic studies of malaria parasites have been car-
ried out on parasite lines collected decades ago [10–16]. 
With a resurgence of interest and increased investment 
in understanding the nature of malaria around the world 
[3–9], efforts to collect and characterize recent parasite 
isolates are also on the rise.
The value of phenotypic studies of culture-adapted 
malaria parasites depends, in part, on standardized 
methods to capture parasites and complete representa-
tion of parasite populations in culture-adapted collec-
tions. Since the original description of successful in vitro 
cultivation of P. falciparum parasites more than five dec-
ades ago [39, 40], many improvements and variations 
in methods and tools for culturing parasites have been 
reported, including the benefits of using Albumax over 
heat-inactivated (HI) plasma-supplemented media, the 
potential advantages of starting with lower haematocrit 
(HCT), and routine washing and processing of patient 
blood before adaptation [41–43].
Beyond the need for standardizing adaptation proce-
dures, it is even more important to define what is consid-
ered adapted. In most studies, it is not always clear how 
much time investigators give a population of parasites to 
adapt and what fraction of naturally occurring variations 
in parasites are captured in the adapted culture. Even 
when parasites straight from the arm are initially visible 
in cell culture, it is not always clear which lines will truly 
proliferate successfully and indefinitely, and which lines 
will die off.
To understand the importance of experimental vari-
ables during culture adaptation, fresh incoming patient 
blood samples were divided into aliquots that were sub-
jected to simple and manageable variations in culture 
adaptation. A number of variables were tested including 
initial high versus low haematocrit, initially washed ver-
sus unwashed infected blood from patients, and media 
supplementation with HI-plasma or with Albumax. By 
starting with many patient samples in a centralized hos-
pital setting, it was possible to examine whether other 
variations affected culture adaptation. Such variations 
included initial parasitaemia, age of the donor patient, 
recent exposure to anti-malarials, and delays between 
sample collection and initiation of culture adaptation.
The results show that culture adaptation of freshly col-
lected parasites is highly effective, particularly with 1  % 
haematocrit supplemented with 0.5  % Albumax. When 
working with HI-plasma, it was important to wash the 
incoming patient blood. Culture adaptation was occa-
sionally forgiving of stresses such as delays between 
sample collection and processing and sometimes even 
recent drug treatment. Above all, successful cultivability 
and time to adaptation appear to be intrinsic properties 
of parasites. The present work frames successful experi-
mental conditions for capturing representative new para-
site lines in a field setting.
Methods
Ethical committees
This work was part of the Malaria Evolution in South Asia 
(MESA) programme project, a US NIH International 
Center of Excellence for Malaria Research (ICEMR). The 
study was approved by the ethics boards at Goa Medical 
College and Hospital, the University of Washington, and 
the Division of Microbiology and Infectious Diseases at 
the NIAID (US National Institutes of Health) as well as 
by the Government of India Health Ministry Screening 
Committee (HMSC).
Patient isolates
Following informed consent, blood samples from P. fal-
ciparum-positive patients were collected in Acid Citrate 
Dextrose (ACD) (BD, India) vacutainers by MESA staff 
at Goa Medical College and Hospital (Bambolim, Goa, 
India) from April 2012 to January 2013. Enrolled patients 
ranged in age from 16 to 63 years old with a median and 
mean age of 26 and 32, respectively. MESA staff prepared 
Giemsa-stained thin and thick smears for parasitaemia 
determination and Plasmodium species identification. 
Rapid diagnostic test (RDTs) (Zephyr Biomedicals, Goa, 
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India) were additionally used for the diagnosis of parasite 
species. One of 33 patients was co-infected with both P. 
falciparum and Plasmodium vivax. In two cases, patients 
were treated with an anti-malarial prior to a blood draw. 
The nature of the treatment and the time of treatment 
was available from the study site hospital records (see 
“Results”).
Laboratory facilities at the hospital
The MESA-ICEMR has developed a Biosafety Level 2 
cell culture facility one floor above the medicine wards 
of Goa Medical College and Hospital. To assure sterile 
manipulations, the on-site laboratory has 6 ft NuAire 
Nu-425-600S laminar flow cabinets and HEPA-filter air 
cleaners in the self-contained culture area as well as the 
corridors outside the culture area. The culture hoods are 
routinely tested for quality performance and used for cul-
ture-media preparations, patient blood sample process-
ing, maintenance of parasite cultures, cryopreservation 
of cultures, and thawing of viable frozen parasites.
Cell culture
Parasites were propagated with slight modifications of 
previously established culture methods [39, 40]. Human 
Type A+ fresh frozen plasma and human Type A+ red 
blood cells (RBCs) were purchased from the Rotary 
Blood Bank (New Delhi, India) from healthy individu-
als. RBCs were washed three times with RPMI medium 
under sterile conditions and subjected to quality tests 
(see below) prior to use with patient-derived parasite 
samples. Plasma was heat-inactivated by incubation at 
56  °C for 30  min followed by centrifugation for 10  min 
at 1000×g. In a sterile environment, heat-inactivated 
plasma (HI-plasma) was directly added to RPMI-1640 
at a 1:5 ratio to produce complete media. Albumax I 
and RPMI-1640 medium (HEPES, l-glutamine) were 
purchased from Life Technologies, and the final culture 
medium of 0.5  % Albumax I was further supplemented 
with 0.05 % hypoxanthine (Sigma-Aldrich).
Antibiotics were not added to the media. Antibiotics 
can potentially mask challenges in maintaining steril-
ity and any drop in personnel performance in the cul-
ture facility. Antibiotics are not always specific and can 
also add potentially confounding variables to pheno-
typic and genotypic characterization of culture adapted 
parasites  [44, 45]. It would be understandable if other 
investigators working under more challenging culture 
conditions find it helpful to use antibiotics in their media 
during culture adaptation.
Quality control
HI-plasma and washed heterologous RBC used for cul-
ture media were regularly subjected to quality control to 
ensure their ability to support parasite growth. In brief, 
reference strain P. falciparum 3D7 was propagated with 
the newly prepared HI-plasma-supplemented media and 
washed RBCs for a minimum of two intra-erythrocytic 
cycles. Typically, five- to ten-fold growth was observed 
per 48-h invasion cycle. Patient isolates were randomly 
tested for mycoplasma contamination on a weekly basis.
Variables for optimum culture conditions
As each sample arrived following venous blood draw to 
the on-site culture laboratory, it was aliquoted and sub-
jected to eight different adaptation conditions.
To establish cultures under conditions  1–4 below, 
200 µL of unwashed whole blood was seeded directly in 
10 ml culture flasks under the following conditions (with-
out additional external blood): 
1. 1 % HCT, 20 % HI-plasma-supplemented RPMI-1640 
media;
2. 1 % HCT, 0.5 % Albumax-supplemented RPMI-1640 
media;
3. 0.25  % HCT, 20  % HI-plasma-supplemented RPMI-
1640 media;
4. 0.25  % HCT, 0.5  % Albumax-supplemented RPMI-
1640 media.
The remaining patient blood was first processed to 
remove plasma and white blood cell by centrifugation at 
1000×g for 5 min and three washes with 10 mL of RPMI-
1640 media. Cultures conditions 5–8 were initiated using 
100 µL of packed, washed RBCs per flask with:
5. 1 % HCT, 20 % HI-plasma-supplemented RPMI-1640 
media;
6. 1 % HCT, 0.5 % Albumax-supplemented RPMI-1640 
media;
7. 0.25  % HCT, 20  % HI-plasma-supplemented RPMI-
1640 media;
8. 0.25  % HCT, 0.5  % Albumax-supplemented RPMI-
1640 media.
During culture maintenance, samples (5  µL) were 
removed from concentrated cells every 24–48  h to 
generate Giemsa-stained thin smears. Parasites were 
diluted with fresh media and uninfected RBCs as nec-
essary to keep the parasitaemia below 1  % to prevent 
overgrowth.
Adaptation from fresh blood draw
For a given patient isolate that showed parasites in cul-
ture, two of eight culture flasks were chosen for quan-
titative growth tests. The first flask that reached a 
0.5–1.0  % parasitaemia threshold from two groups 
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(HI-plasma-supplemented media and Albumax-supple-
mented media) was included in the present analysis. Cul-
ture 1 for Growth Test 1 was chosen from conditions 1, 
3, 5, or 7 (HI-plasma-supplemented media, called Group 
1). Culture 2 for Growth Test 1 was chosen from condi-
tions 2, 4, 6, or 8 (Albumax-supplemented media, called 
Group 2).
Tests for successful adaptation
Before formal growth tests began, when parasitaemia in 
a given patient-derived culture 1 or culture 2 reached 
>0.5  % for the first time, it was passaged to 0.25  % 
parasitaemia through the addition of the appropriate 
amount of fresh RBCs. For cultures with high initial 
patient parasitaemia (greater than 0.5 %), this first pas-
sage typically occurred on Day 1 or 2 to prevent initial 
overgrowth. Otherwise, the initial recovery to 0.5–
1.0 % parasitaemia took as few as 8 days or as many as 
30 days.
When parasitaemia first rebounded to 0.5–1.0 % para-
sitaemia, the culture was ready for Growth Test 1. This 
was initiated by reducing the parasitaemia to 0.25 % and 
determining parasitaemia 48  h later. Successful passage 
of Growth Test 1 required a four-fold increase in para-
sitaemia within a span of 48 h. Growth Test 2 was then 
immediately initiated by again reducing parasitaemia to 
0.25 %. Successful passage of Growth Test 2 also required 
a minimum of four-fold increase in parasitaemia within 
48 h. If a culture did not pass either Growth Test 1 or 2, 
a third growth test was conducted. Those cultures that 
failed multiple growth tests were tracked for a minimum 
of 35 days and then discontinued.
Cryopreservation and thawing of samples
Unadapted parasites, were cryopreserved following 
venous blood draw and processing. Briefly, RBCs were 
spun at 1300×g and the supernatant media was removed. 
An equal volume of Glycerolyte 57 was added and solu-
tion was transferred to a cryovial. Long-term storage 
was under −80 °C or liquid nitrogen conditions. At later 
dates, the cryopreserved parasites were revived from 
−80 °C by palm thawing (~2 min), followed by transfer to 
a 15 mL centrifuge tube and drop-wise addition of one-
fifth volume of 12 % NaCl. Ten mL of 1.6 % NaCl were 
added to the sample and this parasite solution was centri-
fuged at 1000×g for 5 min. The supernatant was removed 
and the RBC pellets were re-suspended with 10  mL of 
RPMI-1640. After a final centrifugation at 1000×g for 
5 min, the thawed cells were introduced into culture with 
10  mL of HI-plasma supplemented media at 2  % HCT. 
Maintenance and microscopic analysis was performed on 
each culture every 48 h. Growth tests were completed as 
discussed above.
Genotyping of parasites
For an additional quality check of the present collec-
tions, which were largely made up of clonal parasites, 
DNA microsatellite analysis was used [46]. The analysis 
was first performed both on Day 0 samples, involving 
DNA preparations directly from the arm of the patient, 
and then again after adaptation to assure that adapted 
parasite genotypes in this low endemicity area were well 
represented in this collection, that there was no selec-
tive enriching of subpopulations of parasites from a few 
patients leaving other subpopulations behind, and most 
importantly that there was no cross-contamination 
between patient samples or from standard cell lines 
growing in the laboratory.
Data capture and analysis
Demographic, diagnostic and clinical data were cap-
tured and managed using REDCap [47]. LabKey software 
was used for culture adaptation data storage, analysis 
and organization [48]. GraphPad Prism 6 was used for 
statistical analyses (unpaired t test and ANOVA) of the 
data presented in this report. The study data were avail-




Venous blood samples were collected from Plasmo-
dium-positive individuals at Goa Medical College and 
Hospital, a tertiary care hospital with diverse malaria 
presentations, but no prior experience in laboratory-
based parasite characterization. In addition to species 
determination in the hospital, all patients were retested 
for P. falciparum or mixed infection by repeat smear and 
RDT performed by MESA laboratory staff. The present 
study involved 33 patients infected with P. falciparum, 
one of which was a mixed infection with both P. falcipa-
rum and P. vivax. Each patient sample was used to seed 
and test eight flasks under different initial culture con-
ditions (see “Methods” and Fig.  1). After that, all cul-
tures were monitored for emerging new parasites every 
24–48 h by light microscopy.
Quantitative criteria for adaptation
In an analysis of fresh blood draw adaptations, out of 33 
patient samples, 21 (~65  %) showed successful growth 
in at least one of the eight conditions tested (Table  1). 
Natural isolates of P. falciparum were considered adapted 
upon four-fold increases in parasitaemia over two 48-h 
time periods (see “Methods” and Fig. 1). This criteria was 
based on early experiences which suggested that a lower 
two-fold increase in parasitaemia was not a reliable pre-
dictable of stable future growth in culture and that a full 
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ten-fold increase in growth took longer than was practi-
cal (unpublished data). To keep workloads manageable, 
the two cultures that grew fastest for each patient were 
subjected to the formal growth tests, but the two test 
flasks had to have two different media types: one with 
20  % HI-plasma-supplemented media and another with 
0.5 % Albumax-supplemented media.
Most favorable media conditions
Table 1 shows the outcome of adaptation attempts from 
the 33 patient samples. Culture ID numbers CA1 to 
CA21 were assigned to patient isolates that were formally 
considered adapted. Culture ID numbers NA1 to NA12 
were assigned to patient isolates that did not generate 
adapted parasites.
The aggregate data could be inspected with respect to: 
(1) how often a particular culture condition was repre-
sented in the most favorable adaptation protocol (con-
ditions 1–8, see “Methods”); or, (2) how long it took for 
parasites to pass the formal growth tests. Of the parasite 
isolates that adapted, some conditions were clearly more 
favourable to rapid adaptation. Either condition 2 or con-
dition 6 (both with 1 % HCT and 0.5 % Albumax) most 
frequently led to efficient culture adaptation. Eighteen 
Fig. 1 Workflow for testing adaptability of Plasmodium falciparum parasites from patients. Between 3 and 6 ml of blood was collected from each 
enrolled patient infected with P. falciparum or mixed co-infection with P. vivax. For direct culture (left path), aliquots of infected blood were used to 
establish 8 cultures under different conditions (See “Methods” and Table 1). For the adaptation from cryopreserved samples (right path), two inde-
pendent researchers each thawed cryogenically preserved patient isolate samples in duplicate. When two cultures reached 0.5–1.0 %, two growth 
tests were conducted. Parasite cultures were maintained for as long as 35 days for adaptation from freshly drawn blood and as long as 45 days to 
allow adaptation from cryopreserved blood
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out of 40 successful outcomes came from culture condi-
tions having 1 % HCT and 0.5 % Albumax, when would 
expect ten out of 40 if all combinations of conditions 
were equally favourable for adaptation. With Albumax, 
it did not matter whether the infected whole blood was 
processed to remove white blood cells (WBCs) and 
Table 1 Most favorable culture conditions and time to adaptation of Plasmodium falciparum parasites, ‘straight from the 
arm’ of 33 patient samples (eight conditions tested per patient)
Condition 1: Unwashed RBCs, HI-plasma, 1 % HCT
Condition 2: Unwashed RBCs, Albumax, 1 % HCT
Condition 3: Unwashed RBCs, HI-plasma, 0.25 % HCT
Condition 4: Unwashed RBCs, Albumax, 0.25 % HCT
Condition 5: Washed RBCS, HI-plasma, 1 % HCT
Condition 6: Washed RBCs, Albumax, 1 % HCT
Condition 7: Washed RBCs, HI-plasma, 0.25 % HCT
Condition 8: Washed RBCs, Albumax, 0.25 % HCT
Culture ID prefix CA- and NA- refer to ‘culture adapted’ and ‘non-culture adapted’, respectively
NGT refers to ‘no growth test’ was performed, as parasitaemia did not reach initiation milestones
Δ indicates that a culture did not pass growth tests during the 35 days of testing
Culture ID Initial parasitaemia (%) Culture 1 Culture 2
Condition Days to adapt Condition Days to adapt
CA1 0.2 2 9 6 Δ
CA2 1.1 2 10 5 10
CA3 1.9 2 11 1 18
CA4 2.6 2 11 3 11
CA5 2.7 2 13 5 13
CA6 13.5 2 16 NGT –
CA7 0.7 2 18 8 18
CA8 3.8 8 20 7 Δ
CA9 0.0 2 22 1 Δ
CA10 0.5 3 21 5 Δ
CA11 3.6 4 12 1 23
CA12 6.0 5 13 8 Δ
CA13 2.6 7 22 5 Δ
CA14 1.9 6 9 6 Δ
CA15 0.1 6 15 1 Δ
CA16 3.3 5 16 6 19
CA17 9.7 6 18 8 Δ
CA18 0.9 6 20 1 22
CA19 1.3 6 20 2 Δ
CA20 9.2 6 23 8 Δ
CA21 0.4 7 33 NGT –
NA1 0.4 NGT – NGT –
NA2 0.2 NGT – NGT –
NA3 0.4 NGT – NGT –
NA4 0.6 NGT – NGT –
NA5 0.0 NGT – NGT –
NA6 0.0 NGT – NGT –
NA7 3.6 NGT – NGT –
NA8 2.0 NGT – NGT –
NA9 0.5 2 Δ NGT –
NA10 1.6 NGT – NGT –
NA11 2.0 6 Δ NGT –
NA12 1.7 5 Δ 7 Δ
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HI-plasma (nine successes for condition 2 and eight for 
condition 6).
From patient arm directly into culture
With HI-plasma, condition  1 (unwashed infected blood 
transferred directly into culture at 1  % HCT with 20  % 
HI-plasma) and condition  3 (unwashed infected blood 
transferred directly into culture at 0.25 % HCT with 20 % 
HI-plasma) were highly under-represented in Table  1. 
This affirms that when it is important to use unwashed 
patient blood samples for culture adaptation in this set-
ting, Albumax is desirable and HI-plasma presents a 
significant liability. This is most likely due to initial com-
plement-mediated red cell lysis rather than effects of the 
medium on parasite growth since parasites adapted suc-
cessfully in the presence of 20  % HI-plasma if the cells 
were washed before placing them in culture. It  is likely 
that small diluted complement in plasma of unwashed 
parasitized patient blood was contributing to lysis when 
the medium had HI-plasma, but not when it had Albu-
max. A comparison of the time it took to pass the growth 
tests showed no difference between cells washed in HI-
plasma versus cells washed in Albumax (Growth Test 1 
and Growth Test 2, Fig. 2).
Each endemic setting often has to determine the type 
of media best suited for the particular research environ-
ment. For practical applications, in principle, Albumax-
supplemented media may be advantageous because it 
is better defined than HI-plasma that comes from ran-
dom in-country donors. The plasma from donors from 
an endemic region could potentially have varying levels 
of invasion blocking antibodies or even circulating anti-
malarials. In addition, unlike Albumax, it can be difficult 
to obtain culture-quality, safe HI-plasma in some set-
tings around the world. The ability of Albumax media 
to support minimally processed parasite containing 
RBCs, even direct whole blood, could further increase 
convenience especially when managing large numbers 
of samples under sterile conditions at a study site in an 
endemic setting. One could further argue that whole 
blood from a malaria patient as an inoculum for cultur-
ing parasites may be better because removal of extracel-
lular components and human cells in human blood may 
hurt adaption by eliminating critical components for 
parasite growth. This is particularly true in light of recent 
new findings on exosome-like particles, which can facili-
tate cellular communications [49, 50]. Indeed, there are 
some indications that HI-plasma-supplemented media 
may be better suited for measuring invasion rates and 
phenotypes associated with virulence [51]. On the other 
hand, in the present setting, there may be advantages 
to washing infected RBCs and removing WBCs, inhibi-
tory immune factors, or anti-malarials that interfere with 
growth. When adaptation occurred, time to adaptation 
was not significantly impacted by media type, RBC levels, 
nor washing of pRBCs (Fig. 2).
Penalties from delayed processing
In the early days of the present project, due to some hos-
pital collections late in the working week and some oper-
ational miscommunication on weekends, samples were 
unintendedly left out for long durations in ACD vacu-
tainers at room temperature. Amongst these were patient 
samples NA1 and NA7, which experienced delayed entry 
into the culture system for 13 and 45 h, respectively, but 
no drug treatment. Delayed processing itself may poten-
tially undermine cultivability. Based on this, hospital-
based collections are now culture-adapted only when 
they arrive at the laboratory in a timely manner. Else-
where in this NIH programme, at more remote locations, 
collections are kept on ice until they reach the appropri-
ate laboratory for processing.
Penalties from prior exposure to anti‑malarials
Of the patient samples studied here, two enrolled 
patients out of 33 had been treated with anti-malarials 
for two to 15 h prior to blood collection by MESA staff 
and they offered surprisingly different outcomes in the 
cultivability tests. It was understandable why NA12 did 
Fig. 2 Time to adaptation is not affected by growth medium. For 
cultures initiated for adaptation from fresh blood draws, pairwise 
comparisons between all possible combinations of protocols showed 
no significant difference in time to adaptation between HI-plasma- 
vs Albumax-supplemented media nor between unwashed (whole 
blood) vs washed pRBCs (p > 0.1). All haematocrits are treated 
together in this data (Table 1)
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not adapt to culture from fresh or from cryopreserved 
samples: the patient providing sample NA12 was treated 
with artesunate and primaquine for 14 h prior to blood 
draw. In contrast, patient sample CA21 had experi-
enced artesunate and mefloquine exposure for 4 h prior 
to blood draw and the sample was not processed for an 
additional 16  h after collection. Surprisingly, the latter 
sample adapted using the two four-fold growth tests, 
though the culture was one of the slowest among the 21 
isolates that adapted (about 30 days; Table 1). It is possi-
ble that during the early hours of drug treatment, a frac-
tion of the population of drug-treated parasites goes into 
a dormant state that gradually comes back to a prolifera-
tive state over time [24]. This experience suggests that 
a complete collection of field samples could, and possi-
bly should, include parasites from drug-treated patients 
because they could reveal mechanisms of dormancy. The 
fraction of parasite samples showing such tolerance for 
drug treatment and exposure to room temperature for an 
extended time in an ACD vacutainer may be small.
Intrinsic variations in adaptability
Freshly drawn blood placed in culture in a timely way and 
without drug exposure allowed parasites to adapt success-
fully, but at significantly different rates (Fig.  3a, left side). 
Overall, of the 33 isolates subjected to tests for ease of 
adaptability straight from the patient arm, two isolates did 
not adapt. Of the remaining 31, some isolates adapted as 
quickly as 8 days and some took as long as 23 days. This sug-
gested that that there may be intrinsic variations amongst 
parasite isolates in adaptability to culture as previously pro-
jected [9, 30]. Of course, it was also possible that some para-
site lines were better matched to the donor RBC or donor 
plasma in the media on the days they were adapted.
The possibility of intrinsic variations amongst parasite 
isolates to adapt to culture was tested differently: Over-
all, out of the original 33 patient-derived parasite samples 
tested earlier for adaptability straight from the patient 
arm, 12 cryopreserved samples were selected for test-
ing for reproducibility of this potential trait. Of these 12 
samples to be retested, 2 had not adapted straight from 
the arm, four had adapted very fast straight from the arm, 
and six had adapted at rates somewhere in between. In 
the retest, all 12 samples were allowed to adapt in paral-
lel in the presence of identical host RBCs and identical 
culture media. The results showed that cryopreserved 
parasite isolates varied predictably in terms of the relative 
time required to adapt (Table 2; Fig. 3a, right side).
While adaptation from cryopreserved parasites was 
generally slower than earlier work from fresh parasites, 
Fig. 3 Time to adaptation varied predictively and reproducibly 
between different patient isolates. a A comparison of pairwise 
time-to-adaptation for parasites from direct blood draws versus from 
cryopreservation. Parasite samples that were subjected to immediate 
adaptation after a blood draw showed the same ranked-tendencies 
compared to cryopreserved immediately after blood draw from the 
patients, when tested together months later in identical media and 
identical host RBCs, the isolates showed roughly the same ranking 
in ease to adaptation. The fastest adapting parasites from some 
fresh patient blood draws (to the left) adapted as quickly as 8 days 
in culture (e.g., CA1 and CA14), others (e.g., CA15, CA16, CA19) took 
15–20 days in culture, and yet others (NA4 and NA11) did not adapt 
at all. For this work, blinded, duplicate samples were adapted by 
each of two different scientists in the laboratory. Samples with a 
history of anti-malarial treatment or prolonged exposure to room 
temperature before sample processing were left out (see “Results”). b 
Cryopreserved parasites from individual patient isolates show large 
but reproducible variations in time to adaptation. For each cryopre-
served patient parasite isolate, the vertical line inside a box represents 
the mean number of days to adaptation. The box around the vertical 
line represents the full spread of days to adaptation for that parasite 
isolate. The raw data is shown in Table 2
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the rank order of isolates for successful culture adapt-
ability was very similar for 10 of the 12 retested parasite 
lines (Fig.  3a). Parasite lines NA4 and NA11, which did 
not adapt earlier, again did not adapt from the cryopre-
served collection, even though the starting parasitaemia 
of 0.6 and 2  %, respectively, was higher than for many 
lines that adapted successfully (Tables  1, 2). Parasites 
CA19, CA15 and CA16, which adapted the slowest when 
placed directly into culture following collection, adapted 
the slowest after months of cryopreservation. Parasite 
lines CA3, CA4, CA14 and CA1, which adapted the fast-
est when placed directly into culture following collection, 
again adapted the fastest after months of cryopreserva-
tion. None of these samples, except CA21 (see above), 
were drug treated and all samples were processed within 
1 h of collection. Thus, variations in culture adaptability 
again pointed to intrinsic properties of the parasites col-
lected from patients.
Reproducibility of variations in adaptability
The reproducibility of adaptation between the differ-
ent patient-derived lines was excellent as was the rank 
order of the adaptability of the parasites preserved after 
months of cryopreservation. Table 2 and Fig. 3b show the 
variation in times to adaptation when a cryopreserved 
aliquot was placed in culture by two different scientists, 
each handling two original sample aliquots from the 
same patient isolate.
To illustrate the speed with which some cryopre-
served patient lines adapted to culture for the first time, 
it is helpful to compare their recovery to that of the pre-
adapted line Dd2 (in red). Figure  3b shows that lines 
CA20, CA6 and CA4 adapted to culture conditions for 
the first time in less than 15  days. Other lines, such as 
CA15 and CA19, took a month longer before they passed 
the formal growth tests.
There were two surprising outliers from the rank order 
patterns (Fig. 3a): patient isolates CA6 and CA20 adapted 
more rapidly after cryopreservation compared to para-
sitized RBCs straight from the arm. These two samples 
came from donor patients with the highest blood para-
sitaemia, 13.5 and 9.2  % respectively, in the sample set. 
It is possible that the washing steps in the process of 
preparing the cryopreserved parasites for culture helped 
remove some parasite-derived inhibitory factors in these 
blood samples with higher parasitaemia.
Overall, after accounting for samples with delayed pro-
cessing and long drug exposure, patient-derived para-
sites were recovered from cryopreservation into culture 
>90  % of the time. In fact, comparing the ten patient 
samples that adapted straight from the arm to adapta-
tion attempts from matched cryopreserved vials, the suc-
cess rate was 100 %. This was very encouraging because 
it allowed the present field-based malaria parasite opera-
tions to decouple sample collection and cryopreservation 
from adaptation. The ability to store and move cryopre-
served parasites facilitates phenotypic characterizations 
that are often conducted by different partners on the 
same cell lines at different times and even at different 
sites.
Table 2 Time to  adaptation of ‘Day 0 cryopreserved blood’ with  Plasmodium falciparum parasites thawed as  duplicate 
replicates and maintained under HI-plasma, 2 % HCT conditions
Culture ID prefix CA- and NA- refer to ‘culture adapted’ and ‘non-culture adapted’, respectively
Δ indicates that a culture did not pass growth tests during the 45 days of testing. Dd2 is a highly drug resistant strain of P. falciparum derived from W2, that grows 
exceptionally well in culture
Culture ID Initial parasitaemia (%) Time to adaptation (days)
Experimenter 1 Experimenter 2 Avg.
Culture 1 Culture 2 Culture 3 Culture 4
Dd2 1.9 13 x 13 x 13.0
CA1 0.2 25 27 27 27 26.5
CA3 1.9 18 15 25 27 21.3
CA4 2.6 15 18 18 18 17.3
CA5 2.7 27 Δ Δ Δ 27.0
CA6 13.5 11 13 13 15 13.0
CA14 1.9 15 15 15 25 17.5
CA15 0.1 29 41 34 41 36.3
CA16 3.3 Δ 27 27 27 27.0
CA19 1.3 42 Δ Δ Δ 42.0
CA20 9.2 11 11 11 11 11.0
NA4 0.6 Δ Δ Δ Δ –
NA11 1.0 Δ Δ Δ Δ –
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Age of patients
In some malaria settings, age is associated with higher 
prior exposure to malaria parasite infections and 
increased protective immunity, as measured by the abil-
ity of antibodies to decrease RBC invasion [52]. It was 
hypothesized that stronger immunity in an older patient 
with P. falciparum could potentially select for parasites 
that use many different RBC invasion pathways efficiently 
and show fast growth in new cellular environments, 
such as first adaptation with donor blood. When culture 
adaptability of different parasites emerging from patients 
of different age groups was compared, a significant cor-
relation was seen: parasites from older patients adapt to 
culture faster (Fig.  4, upper panel). This relationship is 
significant, but it did not hold when cryopreserved para-
sites, with greater scatter in the surviving parasites, were 
retested for adaptability (Fig.  4, lower panel). The over-
all longer adaptation times from cryopreserved parasites 
suggest that there was partial loss of viable parasites in 
cryopreserved samples, but it remains to be seen if there 
is disproportionate loss of parasite viability and cultiva-
bility in frozen samples from more aged patients. Overall, 
compared with age, intrinsic properties of parasites may 
contribute much more to the speed with which parasites 
adapt in culture.
Parasitaemia of patients
It was possible that time to adaptation could be signifi-
cantly affected by initial parasitaemia. Parasites from a 
patient, when placed in culture, have to deal quickly with 
acclimatizing to RBCs from a different donor and plasma 
from yet another donor. Adaptation may involve recon-
figuring invasion processes to match initial culture con-
ditions. Switch rates for invasion processes are related 
to numbers of parasites under selection [53]. It was 
hypothesized that a population of parasite cells at very 
low parasitaemia would not have significant variations in 
invasion ligands or pathways to overcome the challenges 
of adaption.
No direct relationship was seen between initial parasi-
taemia and time to adaptation of a sample (Fig. 5, upper 
panel). In fact, sample CA9, in which parasitaemia was 
barely visible and incalculable by thin smear, adapted by 
day 22 or as quickly as some parasites that had as much 
as 100× higher starting parasites. Cryopreserved para-
sites with high parasitaemia showed a small, but signifi-
cant, increase in adaptability (Fig. 5b). This appeared to 
be due to a decrease in viability of parasites at low para-
sitaemia during the cryopreservation process and, thus, 
poor adaptability from surviving cells. Overall, these data 
are consistent with the earlier indication that intrinsic 
properties of parasites may contribute the most to rapid 
adaptation in culture.
Application to field operations
Based on these foundations, more streamlined proce-
dures have been developed for adaptation of patient-
derived parasites being collected at Goa Medical College 
and Hospital and at the other MESA-ICEMR field sites in 
South Asia. It is important to have a collection of para-
sites that has grown in HI-plasma conditions as well as 
Albumax conditions to minimize deviations from physi-
ological conditions found in blood. The work flow uti-
lizes two initial culture conditions: patient samples are 
routinely placed under culture condition 5 (washed, 1 % 
HCT, 20 % HI-plasma) and culture condition 6 (washed, 
1  % HCT, 0.5  % Albumax) immediately after washing 
patient blood with RPMI 1640 medium under sterile 
conditions to remove WBCs and HI-plasma. While it 
Fig. 4 Time to adaptation was shorter in parasites derived from older 
patients than in parasites from younger donors. a Patient samples 
adapted straight from fresh blood draws showed faster time to adap-
tation in patients above the age of 32 than below the age of 32. b 
Patient samples adapted after cryopreservation had a less significant 
relationship between speed of adaptation and the age of the donor
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would be easier to simply work under Culture Condi-
tion 2 (unwashed, 1 % HCT, 0.5 % Albumax), the labora-
tory facility at Goa Medical College and Hospital allows 
the luxury of washing every sample under sterile condi-
tions for a variety of downstream applications and nested 
studies.
Conclusions
In a first study of its kind, a formal definition of culture 
adaptation was established and these criteria were used 
to examine determinants of successful culture adap-
tation. Even in the first attempt at a new site, parasites 
from ~65  % of tested patient samples successfully 
adapted.
Amongst the successfully adapted parasite lines, there 
were large variations in time to adaptation. Although 
the cryopreserved lines adapted slightly more slowly, 
the rank order for time to successful adaptation was 
mostly preserved. The collective data suggest that intrin-
sic properties of parasites may play a major role in suc-
cessful adaptation. Other variables, such as parasitaemia 
levels in a patient, did not influence the ability to adapt 
nor time to successful adaptation. Parasites derived from 
older patients, possibly with higher immunity, adapted 
significantly faster than parasites collected from younger 
patients.
The mechanisms underlying these variations in adapt-
ability will be the focus of future detailed studies. In the 
meantime, the procedures adopted following this study 
are being used at multiple study sites of the MESA-
ICEMR programme with larger sample sets and for geno-
typic and phenotypic characterization of field-derived 
parasite lines.
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